Review



md2 int 1  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    MedChemExpress md2 int 1
    ( A ) Detection of HMGB1 in CM from a panel of prostate cancer (CaP) cell lines, including LNCaP control (PCMV vector) and <t>MD2-overexpressing</t> cells (M2 vector). ( B ) HMGB1 levels in CM from DU145 control cells (SCR-siRNA) and MD2-silenced cells (MD2 siRNA). ( C ) Levels of soluble MD2 (sMD2) and HMGB1 in CM from LNCaP cells overexpressing MD2 after treatment with the MD2 inhibitor <t>(MD2-int-1)</t> or vehicle control for 24 h.
    Md2 Int 1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/md2 int 1/product/MedChemExpress
    Average 93 stars, based on 7 article reviews
    md2 int 1 - by Bioz Stars, 2026-05
    93/100 stars

    Images

    1) Product Images from "Targeting MD2 in prostate cancer bone metastasis: Mechanistic insights and therapeutic potential"

    Article Title: Targeting MD2 in prostate cancer bone metastasis: Mechanistic insights and therapeutic potential

    Journal: Oncoscience

    doi: 10.18632/oncoscience.647

    ( A ) Detection of HMGB1 in CM from a panel of prostate cancer (CaP) cell lines, including LNCaP control (PCMV vector) and MD2-overexpressing cells (M2 vector). ( B ) HMGB1 levels in CM from DU145 control cells (SCR-siRNA) and MD2-silenced cells (MD2 siRNA). ( C ) Levels of soluble MD2 (sMD2) and HMGB1 in CM from LNCaP cells overexpressing MD2 after treatment with the MD2 inhibitor (MD2-int-1) or vehicle control for 24 h.
    Figure Legend Snippet: ( A ) Detection of HMGB1 in CM from a panel of prostate cancer (CaP) cell lines, including LNCaP control (PCMV vector) and MD2-overexpressing cells (M2 vector). ( B ) HMGB1 levels in CM from DU145 control cells (SCR-siRNA) and MD2-silenced cells (MD2 siRNA). ( C ) Levels of soluble MD2 (sMD2) and HMGB1 in CM from LNCaP cells overexpressing MD2 after treatment with the MD2 inhibitor (MD2-int-1) or vehicle control for 24 h.

    Techniques Used: Control, Plasmid Preparation



    Similar Products

    93
    MedChemExpress md2 int 1
    ( A ) Detection of HMGB1 in CM from a panel of prostate cancer (CaP) cell lines, including LNCaP control (PCMV vector) and <t>MD2-overexpressing</t> cells (M2 vector). ( B ) HMGB1 levels in CM from DU145 control cells (SCR-siRNA) and MD2-silenced cells (MD2 siRNA). ( C ) Levels of soluble MD2 (sMD2) and HMGB1 in CM from LNCaP cells overexpressing MD2 after treatment with the MD2 inhibitor <t>(MD2-int-1)</t> or vehicle control for 24 h.
    Md2 Int 1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/md2 int 1/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    md2 int 1 - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    Image Search Results


    ( A ) Detection of HMGB1 in CM from a panel of prostate cancer (CaP) cell lines, including LNCaP control (PCMV vector) and MD2-overexpressing cells (M2 vector). ( B ) HMGB1 levels in CM from DU145 control cells (SCR-siRNA) and MD2-silenced cells (MD2 siRNA). ( C ) Levels of soluble MD2 (sMD2) and HMGB1 in CM from LNCaP cells overexpressing MD2 after treatment with the MD2 inhibitor (MD2-int-1) or vehicle control for 24 h.

    Journal: Oncoscience

    Article Title: Targeting MD2 in prostate cancer bone metastasis: Mechanistic insights and therapeutic potential

    doi: 10.18632/oncoscience.647

    Figure Lengend Snippet: ( A ) Detection of HMGB1 in CM from a panel of prostate cancer (CaP) cell lines, including LNCaP control (PCMV vector) and MD2-overexpressing cells (M2 vector). ( B ) HMGB1 levels in CM from DU145 control cells (SCR-siRNA) and MD2-silenced cells (MD2 siRNA). ( C ) Levels of soluble MD2 (sMD2) and HMGB1 in CM from LNCaP cells overexpressing MD2 after treatment with the MD2 inhibitor (MD2-int-1) or vehicle control for 24 h.

    Article Snippet: Once tumors were established, as confirmed by IVIS bioluminescence imaging, mice were randomized to receive either vehicle or the selective small molecule MD2 inhibitor, MD2-int-1 (MedChemExpress), for three weeks.

    Techniques: Control, Plasmid Preparation